These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 23148232)

  • 21. Bortezomib Inhibits Open Configurations of the 20S Proteasome.
    Henderson LW; Gautam AKS; Sharon EM; Johnson CR; Rommel NG; Anthony AJ; Russell DH; Jarrold MF; Matouschek A; Clemmer DE
    J Am Soc Mass Spectrom; 2024 Jun; 35(6):1063-1068. PubMed ID: 38748611
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proteasome inhibition correlates with intracellular bortezomib concentrations but not with antiproliferative effects after bolus treatment in myeloma cell lines.
    Dettmer S; Theile D; Schäfer J; Seckinger A; Burhenne J; Weiss J
    Naunyn Schmiedebergs Arch Pharmacol; 2016 Oct; 389(10):1091-101. PubMed ID: 27422413
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biologic impact of proteasome inhibition in multiple myeloma cells--from the aspects of preclinical studies.
    Hideshima T; Anderson KC
    Semin Hematol; 2012 Jul; 49(3):223-7. PubMed ID: 22726545
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Indirubin-3'-monoxime acts as proteasome inhibitor: Therapeutic application in multiple myeloma.
    Yu Z; Wei X; Liu L; Sun H; Fang T; Wang L; Li Y; Sui W; Wang K; He Y; Zhao Y; Huang W; An G; Meng F; Huang C; Yu T; Anderson KC; Cheng T; Qiu L; Hao M
    EBioMedicine; 2022 Apr; 78():103950. PubMed ID: 35344764
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Proteasome inhibitors: introduction.
    Heuck CJ; Shaughnessy JD
    Semin Hematol; 2012 Jul; 49(3):193-5. PubMed ID: 22726541
    [No Abstract]   [Full Text] [Related]  

  • 26. Synthesis and pharmacology of proteasome inhibitors.
    Rentsch A; Landsberg D; Brodmann T; Bülow L; Girbig AK; Kalesse M
    Angew Chem Int Ed Engl; 2013 May; 52(21):5450-88. PubMed ID: 23526565
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structure-based design of human immuno- and constitutive proteasomes inhibitors.
    Richy N; Sarraf D; Maréchal X; Janmamode N; Le Guével R; Genin E; Reboud-Ravaux M; Vidal J
    Eur J Med Chem; 2018 Feb; 145():570-587. PubMed ID: 29339252
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Computational Approaches for the Discovery of Human Proteasome Inhibitors: An Overview.
    Guedes RA; Serra P; Salvador JA; Guedes RC
    Molecules; 2016 Jul; 21(7):. PubMed ID: 27438821
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proteasome inhibitors with photocontrolled activity.
    Hansen MJ; Velema WA; de Bruin G; Overkleeft HS; Szymanski W; Feringa BL
    Chembiochem; 2014 Sep; 15(14):2053-7. PubMed ID: 25125335
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design, synthesis, and biological evaluation of novel phenol ether derivatives as non-covalent proteasome inhibitors.
    Yu J; Xu L; Hong D; Zhang X; Liu J; Li D; Li J; Zhou Y; Liu T
    Eur J Med Chem; 2019 Jan; 161():543-558. PubMed ID: 30391816
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimization of piperidine constructed peptidyl derivatives as proteasome inhibitors.
    Zhao Y; Xu L; Zhang J; Zhang M; Lu J; He R; Xi J; Zhuang R; Li J; Zhou Y
    Bioorg Med Chem; 2021 Jan; 29():115867. PubMed ID: 33223460
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lessons Learned from Proteasome Inhibitors, the Paradigm for Targeting Protein Homeostasis in Cancer.
    Kambhampati S; Wiita AP
    Adv Exp Med Biol; 2020; 1243():147-162. PubMed ID: 32297217
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design, synthesis, and evaluation of cystargolide-based β-lactones as potent proteasome inhibitors.
    Niroula D; Hallada LP; Le Chapelain C; Ganegamage SK; Dotson D; Rogelj S; Groll M; Tello-Aburto R
    Eur J Med Chem; 2018 Sep; 157():962-977. PubMed ID: 30165344
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of the Proteasome β2 Site Sensitizes Triple-Negative Breast Cancer Cells to β5 Inhibitors and Suppresses Nrf1 Activation.
    Weyburne ES; Wilkins OM; Sha Z; Williams DA; Pletnev AA; de Bruin G; Overkleeft HS; Goldberg AL; Cole MD; Kisselev AF
    Cell Chem Biol; 2017 Feb; 24(2):218-230. PubMed ID: 28132893
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
    Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M
    Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells.
    Chauhan D; Tian Z; Zhou B; Kuhn D; Orlowski R; Raje N; Richardson P; Anderson KC
    Clin Cancer Res; 2011 Aug; 17(16):5311-21. PubMed ID: 21724551
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design and synthesis of tripeptidyl furylketones as selective inhibitors against the β5 subunit of human 20S proteasome.
    Sun Q; Zhou T; Xi D; Li X; Lü Z; Xu F; Wang C; Niu Y; Xu P
    Eur J Med Chem; 2020 Apr; 192():112160. PubMed ID: 32146375
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis and mechanistic studies of quinolin-chlorobenzothioate derivatives with proteasome inhibitory activity in pancreatic cancer cell lines.
    Hu S; Jin Y; Liu Y; Ljungman M; Neamati N
    Eur J Med Chem; 2018 Oct; 158():884-895. PubMed ID: 30253345
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis and antiproteasomal activity of novel O-benzyl salicylamide-based inhibitors built from leucine and phenylalanine.
    Jorda R; Dušek J; Řezníčková E; Pauk K; Magar PP; Imramovský A; Kryštof V
    Eur J Med Chem; 2017 Jul; 135():142-158. PubMed ID: 28441582
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ridaifen-F conjugated with cell-penetrating peptides inhibits intracellular proteasome activities and induces drug-resistant cell death.
    Tanaka M; Zhu Y; Shionyu M; Ota N; Shibata N; Watanabe C; Mizusawa A; Sasaki R; Mizukami T; Shiina I; Hasegawa M
    Eur J Med Chem; 2018 Feb; 146():636-650. PubMed ID: 29407987
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.